Regulatory coverage on Peptide News Digest tracks how the FDA, MHRA, EMA, and state agencies handle peptides — what they let through, what they pull, what they redefine.
The compounding fight has dominated 2025 and 2026. GLP-1s came off the FDA shortage list in early 2025; the agency moved compounded semaglutide and tirzepatide toward Category 2 on the 503A bulks list; and a wave of state legislation tried to either preserve or shut off telehealth access. The PCAC has spent meetings on BPC-157, GHK-Cu, and other research peptides that have built consumer demand without clinical infrastructure behind them.
Stories here name the agency, the substance, and the action. Browse the latest below, or jump to specific tags like #fda, #compounding, #peptide-policy, or #503a.
Orrick published a May 2026 client memo walking through the FDA's April 30 proposal to formally exclude semaglutide (Ozempic, Wegovy), tirzepatide (Mounjaro, Zepbound), and liraglutide (Victoza, Saxenda) from the 503B outsourcing-facility bulk drug substances list. The memo flags that the FDA declared the tirzepatide shortage resolved in October 2024 and the semaglutide shortage resolved in February 2025, removing the two legal pathways that previously enabled large-scale compounding. Orrick advises weight-loss clinics, medical spas, and telehealth platforms still relying on compounded GLP-1 products to consult counsel ahead of the June 29 comment deadline.
The FDA's PCAC public docket FDA-2025-N-6895 is now accepting written comments on the proposed addition of seven peptides to the Section 503A bulk drug substances list ahead of the July 23–24 advisory committee meeting at White Oak. Day 1 will cover BPC-157, KPV, TB-500, and MOTs-C; Day 2 will cover Emideltide (DSIP), Semax, and Epitalon. Comments received by July 9 are guaranteed to be presented to the committee, and the docket closes July 22. The window gives compounders, prescribers, and patient advocates roughly twelve weeks to formally submit clinical evidence, pharmacovigilance data, and access arguments.
The FDA announced a proposal on April 30 to exclude semaglutide, tirzepatide, and liraglutide from the 503B outsourcing-facility bulks list, finding no clinical need for large-scale compounding now that branded supply has stabilized. Commissioner Marty Makary said outsourcing facilities cannot lawfully compound from bulk substances when FDA-approved drugs are available unless a clear clinical need exists. Public comments are open through June 29, 2026. The proposal targets 503B outsourcing facilities only and does not directly affect 503A patient-specific compounding, but it forecloses the largest legal pathway for branded-active GLP-1 compounding.
Crinetics Pharmaceuticals announced April 27 that the European Commission approved Palsonify (paltusotine), a selectively-targeted somatostatin receptor type 2 nonpeptide agonist, as the first once-daily oral therapy for acromegaly in adults across all 27 EU member states plus three EEA countries. The approval rests on two pivotal Phase 3 trials in medical-naïve and previously treated patients, with diarrhea, abdominal pain, and nausea reported as the most common adverse reactions and no serious adverse events in the randomized portion. First launches are planned for Germany and Austria, marking Crinetics' first regulatory approval outside the U.S. and a competitive challenge to injectable somatostatin analogs.
STAT News published an April 29 First Opinion piece arguing that the FDA's pending peptide reclassifications — driven by HHS Secretary RFK Jr.'s public enthusiasm for compounds like BPC-157 and GHK-Cu — risk reopening access to inadequately-tested compounds. The op-ed highlights specific safety concerns flagged in the FDA's original 2023 Category 2 designations: immunogenicity, impurities, and the absence of meaningful human clinical data. The piece is positioned as scientific-community pushback ahead of the July 23-24 PCAC meeting that will rule on seven peptides.
The FDA announced April 28 that it has completed first tests of a real-time data system that allows agency scientists to view safety and effectiveness data from clinical trial patients as it is collected — shifting from the traditional stop-and-go batch reporting model to a continuous live data stream. The pilot affects all therapeutic categories including peptide drugs, with implications for trial timelines, regulatory review speed, and adverse-event detection. Industry observers see the move as part of broader systemic agency change under the new HHS leadership.
FormBlends, a telehealth platform focused on medically supervised GLP-1 and peptide therapy, released its 2026 State of Peptides and GLP-1 Regulation Report on April 28. The report maps how RFK Jr.'s HHS, the FDA Center for Drug Evaluation and Research, and the next-generation obesity pipeline from Eli Lilly, Novo Nordisk, Boehringer Ingelheim, and Roche are reshaping legal access for weight management, metabolic health, and peptide therapy through the end of the decade. The report follows the April 22 formal removal of 12 peptides from FDA Category 2 and previews the July 23-24 PCAC meeting.
Pharmacy law firm Holt Law published a detailed regulatory analysis of how the FDA's April 22 Category 2 removals interact with state pharmacy boards, 503A vs 503B compounding pathways, and physician prescribing requirements. The analysis emphasizes that Category 2 removal is not the same as 503A bulk-list inclusion, and that compounding pharmacies face material legal risk if they begin producing reclassified peptides before the July 23-24 PCAC meeting. The piece is a working reference for pharmacy operations preparing for the post-PCAC environment.
JustCare Health published a substantial analysis of the FDA's evolving peptide stance, framing the Category 2 removal as a practical inflection point that begins to resolve the gray-market dynamic that built up after the 2023 restrictions. The piece documents the Alliance for Pharmacy Compounding's position and emphasizes the gap between compounding-pharmacy operational readiness and patient demand. The piece is among the most-read peptide policy articles in the consumer-health press this week.
WHO's December 2025 first-ever GLP-1 guideline for obesity treatment in adults — published as a JAMA Special Communication and updated through Q1 2026 — continues to influence national and payer policy. WHO issued conditional recommendations for chronic GLP-1 therapy as part of comprehensive obesity management, while flagging cost, long-term safety, health-system preparedness, and equity implications. The framework directly informs the political economy of the U.S. Medicare Bridge program extension to 2027 and similar coverage debates globally.
An ABC News-syndicated piece featuring emergency physician and medical toxicologist Dr. Stephanie Widmer ran across ABC affiliates including ABC7 San Francisco, ABC11 Raleigh-Durham, ABC7 Los Angeles, ABC7 Chicago, and ABC13 Houston this week. The piece flagged falsified peptide products tested at arsenic levels up to 10× the toxicity limit for injectables, lead contamination, purity ranging from 5–75%, and documented mislabeling. Cited safety concerns include cardiovascular strain, insulin resistance, psychiatric instability, and blood clots. The breadth of the broadcast parallels FOX's syndicated explainer earlier in the week.
On April 24 the FDA awarded three National Priority Review Vouchers to companies developing psychedelic therapies: Compass Pathways (psilocybin for treatment-resistant depression), Otsuka Pharmaceutical, and the non-profit Usona Institute (methylone for PTSD). This is the same voucher program that enabled Lilly's Foundayo (orforglipron) to be reviewed in 50 days. The program's expansion into psychedelics signals FDA's continued willingness to use priority vouchers aggressively for novel mental health and metabolic candidates — with peptide developers watching closely ahead of the July PCAC meeting.
The FDA granted accelerated approval April 23 for Regeneron's Otarmeni (lunsotogene parvec-cwha), a gene therapy for certain forms of genetic hearing loss. Otarmeni is the first gene therapy cleared under the FDA's National Priority Voucher program and will be offered to eligible patients at no cost. The approval validates the priority voucher pathway's applicability beyond GLP-1 drugs and establishes regulatory precedent that peptide developers may invoke if the July PCAC meeting produces favorable reclassification recommendations.
After CVS/Aetna, UnitedHealth, and other insurers declined to participate in the BALANCE five-year pilot, CMS announced the Medicare GLP-1 Bridge program — originally scheduled to end December 31, 2026 — will now be extended through 2027 with the federal government directly paying for seniors' obesity drug coverage. The pivot acknowledges that the insurer-funded pilot structure was untenable; CMS said the extension will allow longer data collection on which patients benefit most before any transition back to private payers.
Yahoo published an April 23 consumer-facing explainer titled "Wait, So Are Peptides Legal Now?" — the most widely-circulated translation of last week's FDA Category 2 removal for a mainstream audience. The piece walks through which 12 peptides were removed from the restricted list, what the July 23-24 PCAC meeting will actually decide, the distinction between reclassification and FDA approval, and the practical implications for compounding pharmacies and patients. The article marks the peptide-regulation story's transition into general consumer awareness.
Hyman, Phelps & McNamara's FDA Law Blog published a comprehensive two-part analysis April 22 walking compounders and peptide industry stakeholders through the Federal Register notice, the July 23-24 PCAC meeting structure, the distinction between Category 2 removal and Section 503A Bulk Drug Substances List inclusion, and the notice-and-comment rulemaking that must follow any PCAC recommendation. The analysis emphasizes that the July 9, 2026 written comment deadline and June 30 oral presentation notification are critical inflection points for industry engagement.
The Trump administration on April 22 cancelled the five-year BALANCE Medicare model that would have had private insurers pay for Wegovy and Zepbound as a regular benefit, after CVS opted out citing a projected $1.4 billion cost over 10 years. Medicare will instead cover the drugs directly through the Medicare GLP-1 Bridge from July 1, 2026 through December 31, 2027, with beneficiaries paying $50/month copays.
Effective April 22, BPC-157, TB-500, Semax, Epitalon, MOTS-c and seven other peptides were formally removed from the FDA's 503A Category 2 significant-safety-concerns list after original nominators withdrew submissions. The FDA Pharmacy Compounding Advisory Committee will meet July 23-24 to decide whether to add these peptides to the 503A bulks list, which would restore legal compounding under prescription.